Enzo Biochem Signs Marketing Agreement (NYSE:ENZ)

Enzo Biochem Inc (NYSE:ENZ) has announced that they have signed an exclusive marketing deal with privately owned Ikonisys Inc of New Haven, CT. This marketing partnership will cover States of New York and New Jersey and will relate to Ikonisys’ proprietary oncoFISH cervical test, a lab test which has been developed for the treatment and prevention of cervical cancer.

Enzo Biochem, Inc., is a growth-oriented integrated life sciences and biotechnology company focused on harnessing biological process to develop research tools, diagnostics and therapeutics, and serves as a provider of test services, including exotic tests, to the medical community. On the other hand, Ikonisys is a privately owned next generation diagnostic company specializing in non-invasive, cell-based diagnostics. As per the marketing deal, Enzo Clinical Labs will do the marketing of assays to physicians requesting advanced analysis of specimens from liquid based Pap tests to assist them in evaluating cytologic reports.

The assay is based on the identification of a genetic marker, which numerous scientific articles have linked with an increased likelihood for the development of cervical cancer. Hence, running the assay will not require obtaining an additional specimen from patients. MD and President of Enzo Clinical Labs, Kevin Krenitsky said that this marketing agreement is an extension of their lab’s program which broadens their menu of tests in the field of women’s health and that oncoFISH will be able to help the physicians to have better information so that they managed their patients in a better way.